UCI’s largest source of funding, like most research universities, is the U.S. federal government.
Last year, $156.6 million came from the Department of Health & Human Services—a 20% increase over the previous year—continuing the agency's trend as the largest single source of research funding at UCI.
For FY 18-19, about 14% of funding came from non-profit organizations, closely followed by for-profit organizations at nearly 13%. In total 39.6% of support came from non-federal sources.
Carol Booth Olson, professor of education, received $14.7M for an Education Innovation & Research expansion grant from the U.S. Department of Education. The grant will expand the Pathway to Academic Success Project, which helps close reading and writing achievement gaps among high-needs students in grades seven to 11.
$4.6 million was awarded from the Strategic Growth Council of the California Resource Agency, for a multi-institutional project that will develop new tools and methods for better managing the state’s forests and wildlands. Michael Goulden, earth system science professor, is playing a leading role with the creation of the Innovation Center for Advancing Ecosystem Climate Solutions.
A 4-year, $9 million grant aimed at determining the long-term impact of cannabis exposure on the adolescent brain was awarded by the National Institute on Drug Abuse to Daniele Piomelli, professor of anatomy & neurobiology and director of the UCI Center for the Study of Cannabis.
UCI has been named by The Andrew W. Mellon Foundation as the national pilot site for an interdisciplinary team of researchers led by the School of Education to study approaches that will increase our understanding of what makes a liberal arts education so valuable.
Leslie Thompson of the Sue & Bill Gross Stem Cell Research Center and UCI MIND has been awarded $6 million by the California Institute for Regenerative Medicine to continue her CIRM-supported efforts to create stem cell treatments for Huntington’s disease.
Magdalene Seiler received a $4.8 million grant from the California Institute of Regenerative Medicine (CIRM) to continue developing a stem cell-based therapy for retinitis pigmentosa. The therapy may also be applicable to macular degeneration.
|Basic Research||Applied Research||Developmental Research||Other Research||Clinical Trial||Training||Equipment||Other Activity||Fellowship & Scholarship||Total|
For previous years' detail reports, please visit: http://research.uci.edu/about/stats-facts-figures.html